fbpx

Swiss Technology Award for scPharmaceuticals’ Strategic Partner Sensile Medical

Sensile Medical wins as Innovation Leader for micropump at core of    sc2Wear Patch Pump–

LEXINGTON, MA. November 23,    2015– scPharmaceuticals, Inc. today announced that its strategic partner,    Sensile Medical, was awarded the prestigious Swiss Technology Award in the category    “Innovation Leader.” The prize is the most important distinction    for innovation and technology transfer in Switzerland.    The Swiss Innovation Forum’s jury selected Sensile for its SenseCore    technology, a high-precision micropump technology. The award recognizes    outstanding technology-based innovations and developments from start-ups,    universities and technical institutions as well as established businesses.

scPharmaceuticals holds an exclusive world-wide    license from Sensile Medical to the SenseCore technology to develop and commercialize    products for subcutaneous administration of certain classes of    pharmaceuticals. The SenseCore technology is    central to the scPharmaceuticals innovative sc2Wear Patch Pump which allows for    convenient subcutaneous administration of medications that now require intravenous    infusions or intramuscular injections. Intravenous infusions are considered invasive    medical procedures that customarily may only be performed by certified medical    professionals, such as nurses, physicians and EMTs.

The sc2Wear Patch Pump is designed to enable convenient and comfortable controlled    subcutaneous administration of injectable pharmaceuticals without the resources and    costs of intravenous or intramuscular administration. scPharmaceuticals anticipates    submitting two 505(b)(2) NDA product filings to the FDA in 2016. The first product is    the sc2Wear Furosemide Combination Product for treatment of fluid overload (edema)    associated with heart failure. The second product is the sc2Wear Ceftriaxone    Combination Product, which is scPharmaceuticals’ first antibiotic pipeline    product. Ceftriaxone is a widely-used antibiotic for the treatment of infections due    to susceptible pathogens. The sc2Wear Ceftriaxone Patch Pump is intended to reduce    risks and costs associated with antibiotic courses that require daily intravenous    administration by means of a peripherally inserted central catheter (PICC). A PICC,    also called a PIC line, is the standard method to administer ceftriaxone and other    injectable antibiotics when a course of longer duration, typically seven days or    more, is indicated.

For each application, the sc2Wear Pump will    incorporate a unique pre-programmed delivery profile tailored to the    application.

“In 2012 we selected the SenseCore for    application in our patch pump based on a thorough review of relevant core    technologies from around the world”, said Pieter Muntendam, MD, President and    CEO of scPharmaceuticals. “This Award recognizes Sensile as an Innovation    Leader based on their accomplishments in developing transformative controlled drug    delivery devices for use across a broad range of medical    conditions.”

Important Information
scPharmaceuticals’ drug-device combination    products are subject to FDA and other regulatory review and approval prior to    commercial introduction and clinical use.

About scPharmaceuticals:
scPharmaceuticals, Inc. based in Lexington, MA, is a    privately held biopharmaceutical company developing a portfolio of transformative    pharmaceutical products for subcutaneous delivery. Our innovative products are based    on widely used generic drugs that currently require intravenous or intramuscular    injections. They will be administered subcutaneously via the sc2Wear Pump. This    avoids material risks and costs associated with the current delivery options. Our    lead products are the first subcutaneous formulation of furosemide (the most widely    used parenteral diuretic in treating heart failure), and ceftriaxone (the parenteral    antibiotic most widely used outside the hospital setting). Our novel furosemide    formulation enables convenient anytime anywhere use, for example in an outpatient    setting instead of the emergency room or other in-patient settings. For ceftriaxone    and other antibiotics, subcutaneous administration eliminates the need for PICCs    (peripherally inserted central catheters), which are associated with serious    complications, frequent adverse events and high medical costs.

About Sensile Medical:
Sensile Medical based in Haegendorf, Switzerland, is a worldwide leader in Medical    technology. It develops and manufactures high tech micro-pumps for dosing and    delivery of a wide range of parenteral medications. The highly precise technology    developed by Sensile Medical enables the safe and highly accurate delivery of drugs    from very small to large doses. The company was founded in 2004. The company employs    60 people, primarily mechanical and electrical engineers, software developers, and    microsystem mechanics. For further information, go to www.sensile-medical.com

Contact Information:

Katherine Taudvin
Director, Corporate Development
Email: ktaudvin@scpharma.com
Telephone: (781) 301-6706

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge